Model List of Essential Medicines

Amikacin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	**First choice** Neutropaenia (high-risk) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with cefotaxime Inflammatory or other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory or other diseases of prostate (severe)
Antituberculosis medicines ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Multi-drug resistant Mycobacterium tuberculosis

Amoxicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid ◦ Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection ◦ Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate) ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	**First choice** Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock **Second choice** Bacterial meningitis **Other indications** Bacterial infection of unspecified site Infectious cystitis

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection ◦ Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	**First choice** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute sinusitis Other specified pneumonia (Hospital-acquired pneumonia) Chronic obstructive pulmonary disease with acute exacerbation Neutropaenia (low-risk) Peritoneal abscess (mild-moderate) Peritonitis (mild-moderate) Infectious cystitis Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Acute otitis media Other specified prophylactic measures Osteomyelitis or osteitis **Other indications** Bacterial infection of unspecified site
Antituberculosis medicines ◦ Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Multi-drug resistant Mycobacterium tuberculosis

Ampicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension ◦ Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	**First choice** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Peritonitis (severe) **Second choice** Bacterial meningitis **Other indications** Bacterial infection of unspecified site

Azithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)	**First choice** Cholera Cholera [children] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws Trachoma co-prescribed with ceftriaxone Gonococcal infection **Second choice** Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection

Aztreonam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified bacterial diseases

Bedaquiline

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 100 mg tablet; 20 mg tablet	Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection	**First choice** Congenital syphilis [children] Syphilis **Other indications** Bacterial infection of unspecified site

Benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	**First choice** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock **Second choice** Bacterial meningitis **Other indications** Bacterial infection of unspecified site

Capreomycin

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Cefalexin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) ◦ Oral > Solid > dispersible tablet: 125 mg; 250 mg ◦ Oral > Solid: 250 mg (as monohydrate)	**First choice** Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis **Other indications** Bacterial infection of unspecified site

Cefazolin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	**First choice** Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures **Second choice** Bacterial infection of joint Osteomyelitis or osteitis **Other indications** Surgical site infection

Cefepime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection	Other specified bacterial diseases

Cefiderocol

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Cefixime

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)	**Second choice** Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection

Cefotaxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	**First choice** Acute pyelonephritis (severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial pneumonia (Community-acquired pneumonia - severe) Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescribed with amikacin Inflammatory or other diseases of prostate (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) **Second choice** Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis **Other indications** Bacterial infection of unspecified site

Ceftaroline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

Ceftazidime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection	**First choice** Endophthalmitis **Other indications** Pseudomonas aeruginosa resistant to other antibiotic

Ceftazidime + avibactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Ceftolozane + tazobactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g + 0.5 g powder for injection	Carbapenem-resistant Pseudomonas aeruginosa

Ceftriaxone

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)	**First choice** Other specified pneumonia (Hospital-acquired pneumonia) Acute pyelonephritis (severe) Paratyphoid fever Typhoid fever Endophthalmitis Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

◦ Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)	Bacterial meningitis co-prescribed with amikacin Inflammatory or other diseases of prostate (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with metronidazole Necrotising fasciitis co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) **Second choice** Acute pyelonephritis (mild to moderate) Bacterial infection of joint Sepsis without septic shock Infectious gastroenteritis or colitis without specification of infectious agent Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis **Other indications** Bacterial infection of unspecified site

Cefuroxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection	**Second choice** Other specified prophylactic measures

Chloramphenicol

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) ◦ Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection ◦ Oral > Liquid: 150 mg per 5 mL (as palmitate) ◦ Oral > Solid: 250 mg capsule	**Second choice** Bacterial meningitis **Other indications** Bacterial infection of unspecified site

Ciprofloxacin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL (as hyclate) ◦ Oral > Liquid: 250 mg per 5 mL (anhydrous) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride) ◦ Oral > Solid: 250 mg (as hydrochloride)	**First choice** Acute pyelonephritis (mild to moderate) Paratyphoid fever Typhoid fever Infectious gastroenteritis or colitis without specification of infectious agent Neutropaenia (low-risk) Inflammatory or other diseases of prostate (mild to moderate) **Second choice** Cholera Cholera [children] co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate) **Other indications** Bacterial infection of unspecified site

Clarithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection ◦ Oral > Solid > dosage form: 500 mg; 250 mg ◦ Oral > Solid > dosage form: 500 mg	**First choice** co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe) **Second choice** Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe) **Other indications** Helicobacter pylori associated gastric ulcer

Clindamycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate) ◦ Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) ◦ Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) capsule ◦ Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection	**First choice** Necrotising fasciitis **Second choice** Bacterial infection of joint Osteomyelitis or osteitis **Other indications** Bacterial infection of unspecified site

Clofazimine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Multi-drug resistant Mycobacterium tuberculosis
Antileprosy medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Leprosy

Cloxacillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection ◦ Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt) ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	**First choice** Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Sepsis without septic shock **Other indications** Bacterial infection of unspecified site

Colistin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Cycloserine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dosage form: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

Dapsone

Section	Indications
Antileprosy medicines ◦ Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	Leprosy

Daptomycin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Delafloxacin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 300 mg lyophilized powder for injection ◦ Oral > Solid: 450 mg	Methicillin resistant Staphylococcus aureus

Delamanid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 25 mg ◦ Oral > Solid > tablet: 50 mg	Multi-drug resistant Mycobacterium tuberculosis

Dicloxacillin

Section	Indications
Access group antibiotics	**First choice** Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Therapeutic equivalent to cloxacillin for Sepsis without septic shock

Doxycycline

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium) ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection ◦ Oral > Solid > dispersible tablet: 100 mg (as monohydrate) ◦ Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate) ◦ Oral > Solid > dosage form: 100 mg (as hyclate) ◦ Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous) ◦ Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	**First choice** Cholera Chlamydia trachomatis **Second choice** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation **Other indications** Bacterial infection of unspecified site

Eravacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg lyophilized powder for injection	Other carbapenem resistant Enterobacterales

Erythromycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate) ◦ Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate) ◦ Oral > Solid: 250 mg (as stearate or ethylsuccinate)	**Second choice** Therapeutic equivalent to clarithromycin for Acute pharyngitis **Other indications** Bacterial infection of unspecified site

Ethambutol

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)	Other specified tuberculosis Tuberculosis

Ethambutol + isoniazid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 275 mg + 75 mg + 150 mg tablet	Tuberculosis

Ethionamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 125 mg ◦ Oral > Solid > tablet: 250 mg	Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Flomoxef

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection	Other specified other antibiotic resistant Enterobacterales

Flucloxacillin

Section	Indications
Access group antibiotics	**First choice** Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Therapeutic equivalent to cloxacillin for Sepsis without septic shock

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics ◦ .	Other specified bacterial diseases

Gatifloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Gentamicin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	**First choice** Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] **Second choice** Other specified prophylactic measures Gonococcal infection **Other indications** Bacterial infection of unspecified site

Imipenem + cilastatin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	**Second choice** Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Neutropaenia (high-risk) Therapeutic equivalent to meropenem for Peritonitis (severe) **Other indications** Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
Antituberculosis medicines	Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection ◦ Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection	Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Isoniazid

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 100 mg per mL ◦ Oral > Solid > dispersible tablet: 100 mg (scored) ◦ Oral > Solid > tablet: 100 mg; 300 mg	Other specified tuberculosis Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg	Tuberculosis

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 50 mg + 75 mg ◦ Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg	Tuberculosis

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 300 mg + 300 mg tablet (scored)	Latent tuberculosis

Kanamycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Levofloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 250 mg; 500 mg; 750 mg	Multi-drug resistant Mycobacterium tuberculosis

Linezolid

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL in 300 mL bag ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 400 mg tablet; 600 mg tablet ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 600 mg	Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg (scored) ◦ Oral > Solid > tablet: 600 mg	Multi-drug resistant Mycobacterium tuberculosis

Meropenem

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	**Second choice** Neonatal meningitis Peritoneal abscess (severe) Neutropaenia (high-risk) Peritonitis (severe)
Antituberculosis medicines ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant Mycobacterium tuberculosis

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Meticillin

Section	Indications
Access group antibiotics	**First choice** Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Therapeutic equivalent to cloxacillin for Sepsis without septic shock

Metronidazole

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 200 mg per 5 mL (as benzoate) ◦ Local > Rectal > Suppository: 500 mg; 1 g ◦ Parenteral > General injections > unspecified: 500 mg per 100 mL in vial ◦ Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg ◦ Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg ◦ Oral > Solid: 200 to 500 mg tablet ◦ Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection	**First choice** Trichomoniasis Intestinal infections due to Clostridioides difficile Necrotising fasciitis co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe) **Second choice** co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate) **Other indications** Bacterial infection of unspecified site

Moxifloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 400 mg	Multi-drug resistant Mycobacterium tuberculosis Tuberculosis

Nafcillin

Section	Indications
Access group antibiotics	**First choice** Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Therapeutic equivalent to cloxacillin for Sepsis without septic shock

Nitrofurantoin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL oral liquid ◦ Oral > Solid > dosage form: 100 mg; 50 mg	**First choice** Infectious cystitis

Ofloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Omadacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 100 mg lyophilized powder for injection ◦ Oral > Solid: 300 mg	Methicillin resistant Staphylococcus aureus

Oxacillin

Section	Indications
Access group antibiotics	**First choice** Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Therapeutic equivalent to cloxacillin for Sepsis without septic shock

Oxazolindinones

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines ◦ Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution	Multi-drug resistant Mycobacterium tuberculosis

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

Phenoxymethylpenicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid ◦ Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt) ◦ Oral > Solid: 250 mg (as potassium salt) tablet	**First choice** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Periapical abscess without sinus Acute pharyngitis **Other indications** Bacterial infection of unspecified site

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	**First choice** Other specified pneumonia (Hospital-acquired pneumonia) Neutropaenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) co-prescribed with clindamycin Necrotising fasciitis

Plazomicin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg per 10 mL	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Escherichia coli Carbapenem resistant Klebsiella pneumoniae

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Polymyxins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Pretomanid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 200 mg	Multi-drug resistant Mycobacterium tuberculosis

Procaine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	**First choice** Congenital syphilis [children] **Second choice** Syphilis

Protionamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 250 mg (scored)	Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis

Pyrazinamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 400 mg; 500 mg	Tuberculosis

Rifabutin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 600 mg in vial powder for injection ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg	Other specified tuberculosis Tuberculosis
Antileprosy medicines ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg	Leprosy

Rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 150 mg; 300 mg	Latent tuberculosis Tuberculosis

Spectinomycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	**Second choice** Gonococcal infection **Other indications** Bacterial infection of unspecified site

Streptomycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule ◦ Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid ◦ Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet ◦ Oral > Solid > dispersible tablet: 100 mg + 20 mg ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule	**First choice** Infectious cystitis **Second choice** Infectious gastroenteritis or colitis without specification of infectious agent **Other indications** Bacterial infection of unspecified site

Tedizolid

Section	Indications
Reserve group antibiotics	Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus

Terizidone

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > capsule: 250 mg	Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis

Tetracycline

Section	Indications
Access group antibiotics ◦ Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

Tigecycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases

Trimethoprim

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 50 mg per mL ◦ Oral > Solid: 100 mg; 200 mg	**First choice** Infectious cystitis

Vancomycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection ◦ Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride) ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection ◦ Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection	**First choice** Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis **Second choice** Intestinal infections due to Clostridioides difficile Neutropaenia (high-risk) **Other indications** Methicillin resistant Staphylococcus aureus